BioSpace News Archive

AcelRx Pharmaceuticals, Inc. today announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 5,340,591 shares of common stock, at a purchase price of $1.36 per share of common stock, and pre-funded warrants to purchase 2,012,356 shares of common stock at a purchase price of $1.359 per pre-funded warrant (the “Pre-Funded Warrants”).

Twist Bioscience Corporation and Cancer Research Horizons today announced an agreement under which Cancer Research Horizons will license the entire Twist Biopharma Solutions Library of Libraries.

Engrail Therapeutics today announced initiation of a multi-center phase 2 clinical trial, the ENCALM Trial, to evaluate the efficacy and safety of ENX-102 in patients with generalized anxiety disorder (GAD).

Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS) today announced it has completed enrollment in PRECIOSA (NCT03451292), its phase 3 clinical trial designed to determine the potential of long-term albumin treatment with Grifols Albutein® to increase survival time in patients with decompensated cirrhosis and ascites until a suitable transplant is available.

LIXTE Biotechnology Holdings, Inc . today announced it has entered into a securities purchase agreement with a single health-care focused, institutional investor for the purchase and sale of 583,334 shares of common stock.

Duoning Biotechnology Co., Ltd. has used Shanghai Duoning Yuexi Biological Technology Co., Ltd. to sign an agreement to acquire Changzhou PreFluid Technology Co., Ltd., a professional manufacturer of peristaltic pumps, expanding its key product portfolio related to fluid transport and upgrading the fluid management solutions.

Arkuda Therapeutics will present pre-clinical data on lead development candidate ARKD-104 for the treatment of GRN-related frontotemporal dementia (FTD-GRN) at the 2023 Alzheimer’s Association International Conference (Poster P1-752).

OcuTerra Therapeutics, Inc. today announced full enrollment in the company’s Phase 2 DR:EAM (Diabetic Retinopathy: Early Active Management) clinical trial evaluating topically delivered OTT166 eye drops in adult patients with moderately severe to severe non-proliferative diabetic retinopathy (NPDR) or mild proliferative diabetic retinopathy (PDR) with minimal vision loss.

LianBio announced that partner Nanobiotix has entered into a license agreement with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for the investigational, potential first-in-class radioenhancer NBTXR3.

Kaléo announced their selection by the U.S. Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense’s Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical to develop a reconstitution auto-injector device that delivers atropine, the Reconstitution Auto-Injector Device – Atropine.